US00847G7051
© BusinessWire
23.12.2025
AGEN
LISTED
NASDAQ
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC).
The peer-reviewed manuscript titled, “Botensilimab (Fc-enhanced...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
AGEN
LISTED
NASDAQ
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insight...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
AGEN
LISTED
NASDAQ
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes avail...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
10.11.2025
AGEN
LISTED
NASDAQ
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
News Preview
Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spannin...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
05.11.2025
AGEN
LISTED
NASDAQ
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025.
The company also plans to host a stakeholder briefing webcast in late November to provide a corporate and clinical development update. Addi...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
AGEN
LISTED
NASDAQ
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanced CTLA-4 antibody and balstilimab (BAL), a PD-1 inhibitor, combination demonstrating durable survival across multiple cancer types in late-stage patients who have limited treatment options. The resu...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
AGEN
LISTED
NASDAQ
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at 4:00 p.m. ET. The webcast will feature updates from leading experts on recent clinical progress and expanding international access for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL)....
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
AGEN
LISTED
NASDAQ
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) under France’s compassionate access (Accès compassionnel, or AAC) framework. The Frenc...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2025
AGEN
LISTED
NASDAQ
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City.
Dr. Richard Goldberg, Chief Development Officer, and Dr. Robin Taylor, Chief Commercial...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
AGEN
LISTED
NASDAQ
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET which introduces a new virtual format to provide an engaging experience for attendees, along with an updated participation link.
Stakeholder Webcast Participation Details
NEW Audienc...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2025
AGEN
LISTED
NASDAQ
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
AGEN
LISTED
NASDAQ
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive upd...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
29.07.2025
AGEN
LISTED
NASDAQ
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, B.C., July 29, 2025 /CNW/ -- Equity Insider News Commentary – The average age of cancer patients is getting younger, as experts are urgently examining the rise of early-onset incidence across several different cancer types. According to the Cancer Discovery study from the National Cancer Inst...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
AGEN
LISTED
NASDAQ
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – The average age of cancer patients is getting younger, as experts are urgently examining the rise of early-onset incidence across several different cancer types. According to the Cancer Discovery study from the National Canc...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
AGEN
LISTED
NASDAQ
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17-21. The hig...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
AGEN
LISTED
NASDAQ
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
News Preview
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc.
VANCOUVER, BC, July 22, 2025 /CNW/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
AGEN
LISTED
NASDAQ
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
News Preview
Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cance...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
AGEN
LISTED
NASDAQ
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
News Preview
Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus’ lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and ba...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
AGEN
LISTED
NASDAQ
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus’ lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and...
Themefolio
Profiler
Peergroup
© BusinessWire
10.06.2025
AGEN
LISTED
NASDAQ
Agenus Announces Virtual Annual Shareholders Meeting
News Preview
Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders s...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
AGEN
LISTED
NASDAQ
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient acces...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
AGEN
LISTED
NASDAQ
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR),...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
AGEN
LISTED
NASDAQ
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
News Preview
Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Canc...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
AGEN
LISTED
NASDAQ
Agenus Reports Q1 2025 Financial Results and Key Business Updates
News Preview
Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program.
“The growing strength of our BOT/BAL data across m...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
AGEN
LISTED
NASDAQ
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
AGEN
LISTED
NASDAQ
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the resul...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
AGEN
LISTED
NASDAQ
Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
AGEN
LISTED
NASDAQ
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
News Preview
Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
AGEN
LISTED
NASDAQ
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois. A poster presentation will highlight new translational data monitoring induced T-cell dynamics from the botensilimab and ba...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
AGEN
LISTED
NASDAQ
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
AGEN
LISTED
NASDAQ
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
News Preview
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care.
Colorectal cancer remains the second leading cause of cancer-related deat...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
AGEN
LISTED
NASDAQ
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
News Preview
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program....
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
AGEN
LISTED
NASDAQ
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.
Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvir...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
AGEN
LISTED
NASDAQ
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York.
Panel Discussion Details:
Speaker: Robin Taylor, Ph.D., Chief Commercial Officer
Topic: “Wh...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
AGEN
LISTED
NASDAQ
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
AGEN
LISTED
NASDAQ
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
AGEN
LISTED
NASDAQ
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 st...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
AGEN
LISTED
NASDAQ
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
News Preview
Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesday, February 25th, 1:00-1:45 p.m. PST).
The updated release reads:
AGENUS’ BOT/BAL SELECTED FOR TWO PRESENTATIONS AT UPCOMING AACR IO ANNUAL MEETING
Agenus Inc. (Nasdaq: AGEN), a leade...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
AGEN
LISTED
NASDAQ
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These findings further reinforce the consistency of the BOT/BAL combina...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
AGEN
LISTED
NASDAQ
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in co...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
AGEN
LISTED
NASDAQ
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
News Preview
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
AGEN
LISTED
NASDAQ
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
News Preview
Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiati...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
AGEN
LISTED
NASDAQ
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
News Preview
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the trans...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
AGEN
LISTED
NASDAQ
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
News Preview
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024.
“BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where p...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
AGEN
LISTED
NASDAQ
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The dat...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
AGEN
LISTED
NASDAQ
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discu...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
AGEN
LISTED
NASDAQ
Shareholder Rights Law Firm Robbins LLP Reminds AGEN Stockholders with Large Losses They Should Obtain Counsel to Seek Lead Plaintiff Status in the Agenus Inc. Class Action Lawsuit
News Preview
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024. Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the U.S. a...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2024
AGEN
LISTED
NASDAQ
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
AGEN
LISTED
NASDAQ
Agenus Inc. Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the AGEN Class Action Lawsuit
News Preview
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024. Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the U.S. a...
Themefolio
Profiler
Peergroup
© BusinessWire
13.09.2024
AGEN
LISTED
NASDAQ
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor, in combination with bals...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2024
AGEN
LISTED
NASDAQ
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
AGEN
LISTED
NASDAQ
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors wh...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
AGEN
LISTED
NASDAQ
Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024. Agenus describes itself as a “clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in t...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
AGEN
LISTED
NASDAQ
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be featured in a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress, taking place S...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
AGEN
LISTED
NASDAQ
Agenus to Participate in September Investor Conferences
News Preview
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor c...
Themefolio
Profiler
Peergroup
© PR Newswire
15.02.2024
AGEN
LISTED
NASDAQ
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
News Preview
BOSTON and LEXINGTON, Mass., Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, "Adjuvant Acti...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
